Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Stifel raises IDEX Corp to Buy, sees return to growth in 2H24

EditorRachael Rajan
Published 2024-02-08, 09:02 a/m
Updated 2024-02-08, 09:02 a/m
© Reuters.

On Thursday, Stifel upgraded NYSE:IEX, the stock of IDEX (NYSE:IEX) Corp, from Hold to Buy, adjusting the price target to $265 from the previous $215. This move indicates a positive outlook on the company's prospects after a period of challenges in the previous year.

"After a challenging 2023, we see a return to growth in 2H24 with upside to current guidance from market recovery, strong margin expansion ahead with typically high incremental margins early in the cycle, and a return to double-digit organic earnings growth in 2025," said Stifel analysts.

This forecast is based on the company's financial health and its ability to capitalize on market opportunities.

In addition to growth projections, Stifel highlighted the company's substantial balance sheet capacity, which could significantly contribute to long-term earnings growth. The analysts' advice is to "add quality before it's too late," implying confidence in the company's future performance and potential investment returns.

InvestingPro Insights

Following Stifel's upgrade of IDEX Corp (NYSE:IEX) to Buy with a new price target of $265, a closer look at the company through InvestingPro reveals a nuanced financial landscape. An InvestingPro Tip points out that IDEX Corp has raised its dividend for 14 consecutive years, indicating a strong commitment to returning value to shareholders, a factor that may bolster investor confidence in the company's stable financial management.

On the financial metrics front, IDEX Corp boasts a market capitalization of $16.82 billion, underscoring its substantial presence in the industry. The company trades at a high P/E ratio of 31.21 based on the last twelve months as of Q4 2023, suggesting investors may be expecting high future earnings relative to the company's current profit levels. Additionally, the company maintains a solid gross profit margin of 44.24% over the same period, reflecting efficient operations and a strong market position.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

InvestingPro also highlights that the company has been profitable over the last twelve months, which aligns with Stifel's positive growth outlook for IDEX Corp. For investors seeking more detailed analysis and additional InvestingPro Tips – such as the company's moderate level of debt and liquidity position – a visit to https://www.investing.com/pro/IEX is recommended. There are 12 additional tips listed in InvestingPro, providing an in-depth understanding of IDEX Corp's financial health and market potential.

For those interested in an InvestingPro+ subscription, using coupon code SFY24 will secure an additional 10% off a 2-year subscription, or SFY241 for an additional 10% off a 1-year subscription. These offers could be particularly valuable for investors looking to gain a comprehensive insight into companies like IDEX Corp and make informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.